These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expression of CDKN2 gene product in human bronchogenic carcinoma].
    Author: Jiang Y, Xia S, Dai X.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 1996 Apr; 19(2):81-3. PubMed ID: 9388844.
    Abstract:
    OBJECTIVE: To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic carcinoma. METHOD: Using a rabbit polyclonal antibody against P16 (N-20), the expression of P16 protein was studied immunohistochemically on formalin fixed, paraffin embedded sections. RESULTS: The cytoplasmic P16 protein was mainly present in normal bronchial epithelium (93.8%), serous gland (92.6%) and alveolar epithelium (71.4%), the expression levels of P16 were significantly lower in carcinoma tissues (61.9%) when compared to levels in their normal counterparts (P < 0.01). Among tumors, squamous cell carcinomas and small cell carcinomas exhibited lower P16 expression levels compared with adenocarcinomas (P < 0.01). The expression levels of P16 were lower in poorly-differentiated adenocarcinomas compared with those in well-differentiated adenocarcinomas (P < 0.05). CONCLUSIONS: The results suggested that CDKN2 gene was a tumor suppressor gene, the inactivation of which were involved in the carcinogenesis of bronchogenic carcinoma and implicated in tumor differentiation.
    [Abstract] [Full Text] [Related] [New Search]